efficacy and safety of afatinib vs erlotinib and gefitinib in egfr nsclc
Published 7 years ago • 3.7K plays • Length 3:07Download video MP4
Download video MP3
Similar videos
-
17:27
how, when, and where to utilize erlotinib, afatinib, and gefitinib in egfr positive nsclc
-
2:26
elderly patients with egfr-mutated lung cancer: afatinib, gefitinib, erlotinib study | aging-us
-
2:10
reconsideration of gefitinib in egfr-mutant nsclc
-
5:47
egfr tkis for upfront treatment of nsclc
-
4:09
frontline afatinib in egfr-mutant nsclc
-
2:14
lux-lung 7: phase 2b trial of first-line afatinib versus gefitinib for egfr mutation-positive nsclc
-
3:47
afatinib therapy for uncommon egfr alterations in nsclc
-
2:10
afatinib versus erlotinib in patients with advanced scc
-
0:58
the activity of afatinib in lung cancer
-
2:10
role of gefitinib in egrf-mutant disease
-
8:38
afatinib plus cetuximab in resistant non-small cell lung cancer
-
21:41
beyond erlotinib: are second generation egfr inhibitors better or simply newer?
-
6:46
selecting a first-line egfr inhibitor in nsclc
-
1:21
lux-lung 7: phase 2b trial of afatinib versus gefitinib for egfr-mutated lung cancer in first-line
-
1:56
dr. haigentz on the potential of erlotinib and bevacizumab in egfr-mutant nsclc
-
6:28
sequential treatment with afatinib and osimertinib in patients with egfr mutation-positive nsclc
-
2:34
afatinib: dose modifications and adverse events
-
1:31
lux-lung 7: phase 2b trial of afatinib versus gefitinib for egfr-mutated adenocarcinoma of the lung
-
1:35
dr. janjigian discusses afatinib and cetuximab for patients with egfr-mutant lung cancer